Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Occurrence of disputed rpoB mutations among Mycobacterium tuberculosis isolates phenotypically susceptible to rifampicin in a country with a low incidence of multidrug-resistant tuberculosis ; volume:19 ; number:1 ; day:3 ; month:1 ; year:2019 ; pages:1-9 ; date:12.2019
BMC infectious diseases ; 19, Heft 1 (3.1.2019), 1-9, 12.2019
- Urheber
-
Al-Mutairi, Noura M.
Ahmad, Suhail
Mokaddas, Eiman
Eldeen, Hanaa S.
Joseph, Susan
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-018-3638-z
- URN
-
urn:nbn:de:101:1-2019020822130659358681
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:55 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Al-Mutairi, Noura M.
- Ahmad, Suhail
- Mokaddas, Eiman
- Eldeen, Hanaa S.
- Joseph, Susan
- SpringerLink (Online service)
Ähnliche Objekte (12)
Multidrug-resistant tuberculosis
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis
Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis
Correction: Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Tuberculosis out of control : strategies to fight multidrug-resistant tuberculosis
Nomogram to predict multidrug-resistant tuberculosis
Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis
Characteristics of multidrug-resistant tuberculosis in Namibia
Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families
Multidrug-resistant tuberculosis
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis
Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis
Correction: Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Tuberculosis out of control : strategies to fight multidrug-resistant tuberculosis
Nomogram to predict multidrug-resistant tuberculosis
Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis
Characteristics of multidrug-resistant tuberculosis in Namibia
Mycobacterium tuberculosis Uganda II is more susceptible to rifampicin and isoniazid compared to Beijing and Delhi/CAS families
Multidrug-resistant tuberculosis
Different macrophage polarization between drug-susceptible and multidrug-resistant pulmonary tuberculosis
Could high-concentration rifampicin kill rifampicin-resistant M. tuberculosis? Rifampicin MIC test in rifampicin-resistant isolates from patients with osteoarticular tuberculosis
Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis
Correction: Risk factors of adult isoniazid-resistant and rifampicin-susceptible tuberculosis in Nanjing, 2019–2021
Tuberculosis out of control : strategies to fight multidrug-resistant tuberculosis
Nomogram to predict multidrug-resistant tuberculosis
Airway microecology in rifampicin-resistant and rifampicin-sensitive pulmonary tuberculosis patients
Efficacy and safety of shorter multidrug-resistant or rifampicin-resistant tuberculosis regimens: a network meta-analysis
Characteristics of multidrug-resistant tuberculosis in Namibia